Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

BACKGROUND: The efficacy of immune checkpoint inhibitors (ICIs) in patients with microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC) is unprecedented. A relevant proportion of subjects achieving durable disease control may be considered potentially ‘cured’, as opposed to patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietrantonio, Filippo, Lonardi, Sara, Corti, Francesca, Infante, Gabriele, Elez, Maria Elena, Fakih, Marwan, Jayachandran, Priya, Shah, Aakash Tushar, Salati, Massimiliano, Fenocchio, Elisabetta, Salvatore, Lisa, Curigliano, Giuseppe, Cremolini, Chiara, Ambrosini, Margherita, Ros, Javier, Intini, Rossana, Nappo, Floriana, Damian, Silvia, Morano, Federica, Fucà, Giovanni, Overman, Michael, Miceli, Rosalba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386222/
https://www.ncbi.nlm.nih.gov/pubmed/34429334
http://dx.doi.org/10.1136/jitc-2021-003370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386222/
https://www.ncbi.nlm.nih.gov/pubmed/34429334
http://dx.doi.org/10.1136/jitc-2021-003370

Ejemplares similares